Ischemic cardiomyopathy changes how the heart pumps blood because of muscle damage. Learn about the role of medication in ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research ...

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...

People with hypertrophic cardiomyopathy (HCM) have a greater risk of becoming severely ill from COVID-19. Furthermore, the virus has been found to significantly damage the heart muscle, causing ...

A primary school vice-principal has resigned after allegations of him having an extramarital affair with a student's parent surfaced online. Photos of the alleged affair first appeared on Thursday ...

The application seeking approval for vutrisiran to treat ATTR-CM is supported by positive results from ALNY’s pivotal phase III HELIOS-B study, which met all primary and secondary endpoints ...

The regulatory application is based on positive results from the pivotal HELIOS-B Phase 3, randomized, double-blind, placebo-controlled multicenter global study which met all 10 of its primary and ...